Oncolytic virotherapy with reovirus has demonstrated anti-cancer activity and minimal toxicity in clinical trials, but the mechanisms underlying these effects have not been fully elucidated. Reolysin, a proprietary formulation of reovirus for cancer therapy, stimulated selective viral replication and apoptosis in multiple myeloma (MM) cells. Reolysin-mediated apoptosis was associated with an induction of endoplasmic reticular (ER) stress-related gene expression, swelling of the endoplasmic reticulum, increases in intracellular calcium levels and a strong induction of the Bcl-2 homology 3 (BH3)-only pro-apoptotic protein NOXA. Knockdown of NOXA expression by short hairpin RNA significantly reduced the pro-apoptotic effects of Reolysin. We next showed that co-administration of Reolysin and bortezomib resulted in the dual accumulation of viral and ubiquitinated proteins, which led to enhanced ER stress, NOXA induction and apoptosis. Importantly, the combination of reovirus infection and proteasomal inhibition significantly decreased tumor burden in a xenograft and syngeneic bone disease model of MM without exhibiting adverse side effects. Our study establishes ER stress stimulation and NOXA induction as novel mediators of reovirus-induced apoptosis. Furthermore, reovirus infection can be used as a promising approach to augment the anti-myeloma activity of bortezomib by promoting additional stress to the endoplasmic reticulum of MM cells.
Introduction
Reoviruses are ubiquitous viruses that can be found in the respiratory and gastrointestinal tract of humans. However, infections are largely asymptomatic (Kelly et al., 2009) . Previous studies demonstrated that reoviruses selectively replicate in transformed cells and not in normal tissue, suggesting that reoviruses may have anti-cancer activity Strong et al., 1998) . The basis for reovirus to selectively replicate in cancer cells has been attributed to the activated Ras pathway, which inhibits doublestranded RNA-activated protein kinase activation leading to the synthesis of viral proteins. This observation led to the investigation of reovirus as a potential cancer therapeutic in tumors with a high frequency of activated Ras, such as pancreatic cancer (Etoh et al., 2003) .
The reovirus-based formulation Reolysin recently entered phase I and II clinical trials and has demonstrated activity in several cancer types, while being safe and very well tolerated when administered locally or systemically (Forsyth et al., 2008; Vidal et al., 2008) . In addition, a phase III study in head and neck cancer is currently evaluating Reolysin in combination with paclitaxel and carboplatin. Despite the promising potential of reovirus as an anti-cancer agent, it has not been rigorously investigated for the treatment of hematological malignancies, including multiple myeloma (MM) . Previous work in MM has focused on reovirus as a purging strategy for autologous stem cell transplantation (Thirukkumaran et al., 2003) .
MM is a fatal neoplasm characterized by the uncontrolled proliferation of clonal plasma cells and accounts for 13% of hematological malignancies. New agents such as the proteasome inhibitor bortezomib have improved patient response. However, a cure is rarely achieved due to the persistence of residual disease (Kumar et al., 2004) . Recent work indicates that MM cells are under intrinsic endoplasmic reticular (ER) stress due to their production of large amounts of immunoglobulins (Meister et al., 2007; Nawrocki et al., 2008) . Therefore, MM cells may be particularly sensitive to anti-cancer agents that induce ER stress. Investigation of the mechanisms of action of bortezomib has determined that it has pleiotropic cellular effects that contribute to its anti-myeloma activity including inhibition of nuclear factor kB, stimulation of ER stress, induction of the pro-apoptotic Bcl-2 homology 3 (BH3)-only family member NOXA, inhibition of tumor angiogenesis and the disruption of survival signaling cascades (Nawrocki et al., 2002; Hideshima et al., 2003; Qin et al., 2005) . Bortezomib-mediated proteasomal inhibition results in the accumulation of large quantities of ubiquitinated protein aggregates that induce ER stress, which has been reported to be a significant contributor to bortezomib's anti-cancer activity (Nawrocki et al., 2005a (Nawrocki et al., , b, 2008 Fribley et al., 2006; Carew et al., 2010) . As such, we posit that agents with the ability to increase ER stress will possess strong antimyeloma activity and augment bortezomib-mediated cell death.
The mechanism of Reolysin-induced cell death has not been fully characterized. We propose that reovirus replication induces a large accumulation of viral proteins that stimulates ER stress-mediated apoptosis. Given the intrinsic sensitivity of MM cells to ER stress, these cells may be especially vulnerable to reovirusmediated cell death. To test this hypothesis, we investigated the efficacy and mechanism of action of Reolysin in a panel of MM cell lines, primary cells from MM patients, a MM xenograft model and an orthotopic syngeneic MM bone disease mouse model. Here, we show that reovirus infection resulted in ER stress, induction of NOXA and apoptosis. Furthermore, Reolysin strongly enhanced the anti-myeloma activity of bortezomib, which was associated with augmented levels of NOXA and ER stress. Importantly, Reolysin also significantly improved bortezomib's activity in a MM xenograft and bone disease syngeneic mouse model. These findings demonstrate that reovirus has significant activity against MM, augment bortezomibmediated apoptosis and provide the rationale for clinical studies with Reolysin for the treatment of MM.
Results
Reolysin selectively induces viral replication, reduces the viability of MM cells and induces ER stress Reovirus exposure has been reported to induce cell death in a variety of solid tumors, but has not been investigated as a treatment for MM. Reolysin-mediated cell death was associated with significant viral accumulation inside MM cells (Figure 1a ). Reolysin dramatically reduced cell viability in MM cell lines, while displaying much less potency against peripheral blood mononuclear cells (PBMCs) (Figure 1b) . Reovirus infection has been reported to occur via oncolytic and apoptotic pathways, suggesting that it may kill cancer cells via multiple mechanisms (Clarke et al., 2004; Marcato et al., 2007) . Expression profiling analysis of RNA isolated from U266 cells revealed that reovirus treatment induced a strong anti-viral response, which was characterized by interferon (IFN) stimulation (Supplementary Tables 1 and 2 ). Consistent with prior reports, reovirus exposure induces an IFN-b response (Hamamdzic et al., 2001; Holm et al., 2007; Steele et al., 2011) . While IFN production has been reported to decrease viral spread and efficacy, IFNs have also been shown to elicit anti-tumor effects via inhibition of angiogenesis and stimulation of apoptosis (Sidky and Borden, 1987; Taylor et al., 2008; Shmulevitz et al., 2010) . To investigate whether IFN-b contributes to Reolysin-mediated apoptosis, we blocked its activity with neutralizing antibody. IFN-b antibodies did not alter apoptosis induced by Reolysin in U266 and RPMI-8226 MM cells (Figure 1c ). These data suggest that other mechanisms are accounting for the in vitro efficacy of Reolysin in MM cells. Expression profiling analysis also showed significant elevations in the expression of many genes characteristic of ER stress, including CASPASE-4, GADD153/CHOP and GADD34 (Figure 1d ; Supplementary Tables 1 and 2 ). Large amounts of viral proteins are synthesized during viral infection, which may lead to ER stress. Since MM cells are particularly sensitive to ER stress-induced apoptosis due to high rates of protein synthesis, we hypothesized that ER stress induction may be a significant contributor to Reolysin's anti-myeloma activity. Further analyses of gene expression by qRT-PCR (quantitative real-time polymerase chain reaction) confirmed that ER stress-related genes were significantly upregulated following Reolysin treatment in both the U266 and RPMI-8226 cell lines (Figure 1e ). Importantly, ER stress genes, including GADD34, GADD153/CHOP, CASPASE-4 and BiP were also significantly increased in primary CD138 þ cells collected from MM patients and not in normal PBMCs (Figure 1e ).
To further evaluate ER stress induction following Reolysin treatment, we measured other classical features of ER stress. Reolysin exposure promoted ER swelling in U266 cells and not in PBMCs as visualized by electron microscopy (Figure 2a ). Reolysin treatment also led to an increase in intracellular Ca 2 þ levels ( Figure 2b ). Another established marker of ER stress Affymetrix expression arrays revealed a significant increase in ER stress-related genes in U266 cells. Cells were treated for 48 h with 300 PFU/cell Reolysin. Genes associated with ER stress that were significantly upregulated are shown. (e) qRT-PCR analysis of selected ER stress genes that were upregulated (CASPASE-4, GADD153/CHOP, GADD34, HSPA5/BiP). PBMCs, U266, RPMI-8226 or primary CD138 þ cells from three different patients with MM were treated with 300 PFU/cell Reolysin for 48 h and then harvested for analysis. Levels of mRNAs were standardized to the expression of GAPDH. The data are expressed as mean ± s.d., n ¼ 3. *Indicates a significant difference from the controls, Po0.05.
induction is the splicing of X-box binding protein 1 (XBP-1), a key transcriptional regulator of the unfolded protein response. The spliced form of XBP-1 (XBP-1s) is generated by inositol-requiring enzyme 1 to increase the expression of genes involved with protein folding and degradation (Yoshida et al., 2001) . Consistent with Reolysin inducing ER stress, reovirus infection resulted in a significant increase in XBP-1s levels in both the U266 and RPMI-8226 cell lines and in CD138 þ cells collected from MM patients (Figure 2c ). No significant increase was detected in Reolysin-treated PBMCs.
NOXA induction significantly contributes to Reolysininduced apoptosis A number of pro-apoptotic genes have been reported to be induced following ER stress, including the BH3 containing pro-apoptotic bcl-2 family members, NOXA, BIM and PUMA (Reimertz et al., 2003; Li et al., 2006; Puthalakath et al., 2007; Nawrocki et al., 2008; Wang et al., 2009) . qRT-PCR analyses demonstrated a dramatic increase in NOXA expression in the U266 and RPMI-8226 cell lines along with a slight increase in BIM and PUMA (Figure 3a) . Notably, NOXA expression (PMAIP1) was also strongly increased following Reolysin exposure in our gene expression profiling experiment, while there was no significant change in BIM and PUMA (Figure 1d ; Supplementary Table 1) . Based on these data, we hypothesized that NOXA may be a critical mediator of Reolysin-mediated apoptosis in MM cells. To further test this, we evaluated NOXA induction in primary MM cells and in PBMCs. NOXA expression was also strongly induced in primary MM cells and was not significantly induced in PBMCs following Reolysin treatment ( Figure 3b ). Immunoblotting revealed that the basal levels of NOXA are extremely low, but is strongly induced after reovirus infection ( Figure 3c ). As expected, NOXA expression was associated with apoptosis induction as measured by caspase-3 activation ( Figure 3d ). To further establish a regulatory role for NOXA during Reolysin-mediated cell death, short hairpin RNA (shRNA) was utilized to knockdown NOXA expression in the U266 and RPMI-8226 cell lines. Importantly, a reduction in NOXA levels significantly decreased Reolysin-induced apoptosis ( Figure 3e ).
Reolysin and bortezomib promote a simultaneous accumulation of viral and ubiquitinated proteins resulting in increased levels of ER stress Inhibition of proteasomal degradation by bortezomib induces an accumulation of undegraded ubiquitinated proteins, which stimulates ER stress-mediated apoptosis. We hypothesized that the simultaneous accumulation of ubiquitinated and viral proteins would lead to enhanced levels of ER stress and apoptosis. In agreement with our hypothesis, co-treatment with bortezomib and Reolysin resulted in an accumulation of ubiquitinated and reoviral proteins in U266 and RPMI-8226 cells ( Figure 4a ). This result was also confirmed in HeLa cells clearly demonstrating ubiquitinated aggresome Reolysin augments bortezomib-induced ER stress. (a) Reolysin and bortezomib induce the simultaneous accumulation of viral and ubiquitinated proteins. Cells were treated for 24 h with 2 nM BZ, 300 PFU/cell Reolysin or the combination and stained with anti-ubiquitin (green) and anti-reovirus (red) antibodies, and imaged using confocal microscopy with a Â 40 objective. (b) The combination of Reolysin and bortezomib increases BiP expression and XBP-1 splicing. Cells were treated with 2 nM BZ, 300 PFU/cell Reolysin or the combination for 24 h and XBP-1s levels were measured by qRT-PCR. The data are expressed as mean±s.d., n ¼ 3, Po0.05. *Denotes a significant difference compared with controls or **either single agent treatment. (c) Reolysin augments bortezomib-mediated increases in intracellular calcium levels. Cells were treated with 2 nM BZ and 300 PFU/cell Reolysin for 12 h and intracellular calcium levels were determined by staining with calcium green-1 and flow cytometry. The data are expressed as mean±s.d., n ¼ 3. *Indicates a significant difference compared with controls or **single agent treatment, Po0.05. (d) Cycloheximide (CHX) blocks apoptosis induced by the Reolysin, bortezomib and the combination. U266 cells were treated with 2 nM BZ, 300 PFU/ cell Reolysin or the combination for 24 h in the presence or absence of 0.5 mg/ml CHX. Apoptosis was quantified by active caspase-3 staining and flow cytometry. The data are expressed as mean ± s.d., n ¼ 3. *Denotes a significant difference compared with combination-treated cells without CHX, Po0.05.
formation and reovirus replication following combination treatment (Supplementary Figure 1) . Consistent with the dual presence of ubiquitinated and viral proteins, the combination of these agents augmented ER stress levels as measured by increases in BiP expression and XBP-1 splicing (Figure 4b ) and intracellular Ca 2 þ levels ( Figure 4c ). To evaluate whether the continued translation of ubiquitinated and viral proteins was essential for apoptosis, cycloheximide was used to inhibit global protein synthesis. Addition of cycloheximide to bortezomib and Reolysin-treated U266 cells prevented the accumulation of ubiquitinated and viral proteins (data not shown) and resulted in significantly less caspase-3 activation (Figure 4d ). Taken together, these data demonstrate that reovirus replication and ubiquitinated protein accumulation cooperate to induce heightened levels of ER stress.
NOXA is an important regulator of Reolysin and bortezomib-induced apoptosis To evaluate whether Reolysin enhances the antimyeloma activity of bortezomib, we evaluated this combination in U266 and RPMI-8226 cell lines and in primary MM cells. Co-administration of both agents reduced MM cell viability ( Figure 5a ) and promoted increased levels of caspase-3 activation and DNA fragmentation (Figure 5b ). The enhanced activity of the combination was associated with a strong increase in NOXA mRNA and protein expression (Figure 5c ). To determine the contribution of NOXA induction to the anti-myeloma activity of Reolysin and bortezomib, shRNA was utilized to silence NOXA expression in MM cell lines. While stable knockdown of NOXA significantly diminished the pro-apoptotic potential of Reolysin and bortezomib single agent treatments, it had a much more profound effect on the combination of Reolysin and bortezomib (Figure 5d ). This indicates that NOXA is an essential regulator of cellular sensitivity to this therapeutic combination.
Reolysin has in vivo anti-myeloma activity and significantly augments the efficacy of bortezomib We next conducted a xenograft study to investigate the in vivo therapeutic potential of the Reolysin/ the degree of BiP, NOXA and cleaved caspase-3 in RPMI-8226 tumors using an immunohistochemical method. Consistent with the results obtained during our in vitro studies, in vivo treatment with Reolysin stimulated BiP and NOXA expression and triggered activation of caspase-3 in RPMI-8226 tumor cells. Moreover, BiP, NOXA and cleaved caspase-3 induction were significantly greater in tumors from mice treated with the combination of Reolysin and bortezomib over either agent alone (Figures 6c-e) . Together, our data establish that combination therapy with Reolysin and bortezomib is a novel and highly effective approach for the treatment of MM.
Reolysin reduces bone destruction and significantly increases the activity of bortezomib in a syngeneic MM mouse model To further investigate the therapeutic potential of this combination strategy, we utilized the 5TGM1 syngeneic MM mouse model that has been shown to faithfully replicate human disease (Oyajobi et al., 2007) . Similar to human MM cell lines, 5TGM1 cells were moderately sensitive to Reolysin and bortezomib single agent treatment in vitro, but were much more sensitive to the combination of these agents (Figure 7a ). 5TGM1 murine MM cells were generated to stably express enhanced green fluorescent protein (eGFP) (5TGM1-eGFP cells). Inoculation of these cells into immunocompetent mice produces multifocal fluorescent lesions throughout the mouse skeleton. Additionally, these tumors share many clinical, cytogenetic, histologic and molecular features with human MM and secrete IgG2bk immunoglobulin (Dallas et al., 1999) . Reolysin in combination with bortezomib potently diminished IgG2bk immunoglobulin secretion as measured by ELISA (enzyme-linked immunosorbent assay) assay (Figure 7b ). In addition, 5TGM1-eGFP cells homed to the skeletons of mice treated with vehicle control (Figure 7c , top left). Single agent therapy with Reolysin significantly reduced skeletal tumor burden (Figure 7c , bottom left). The addition of Reolysin to bortezomib (0.5 or 1 mg/kg) strongly augmented the anti-myeloma activity of bortezomib (Figure 7c , bottom center and bottom right). Quantification of vertebrae fluorescence revealed a significant reduction in skeletal tumor burden in combination-treated mice (Figure 7d) . Consistent with the lack of efficacy observed in normal PBMCs in vitro, we observed no significant toxicity associated with Reolysin or the combination in vivo. Clinical trials have also reported no severe toxicity associated with Reolysin given alone or in combination with radiation or chemotherapy (Thirukkumaran and Morris, 2009) . Collectively, these results show that the combination of Reolysin and bortezomib is highly effective in a syngeneic mouse model of MM that mimics many of the hallmark features of MM pathogenesis.
Discussion
Here, we describe a novel ER stress-based strategy to increase the therapeutic activity of bortezomib by co-administering the oncolytic virus Reolysin in preclinical models of MM. Reolysin has been established to be safe and well tolerated in multiple early phase clinical studies (Forsyth et al., 2008; Vidal et al., 2008) . It has shown significant anti-cancer activity as a single agent that can be potentiated by concomitant administration of cytotoxic chemotherapy or radiotherapy Pandha et al., 2009) . The mechanisms underlying the anti-cancer effects of reovirus remain to be fully elucidated. Previous studies have determined that reovirus selectively replicates in cells with an activated Ras pathway Strong et al., 1998) . However, recent investigations have suggested that other factors may contribute to the anti-cancer activity of reovirus (Alain et al., 2007; van Houdt et al., 2008) .
While a number of mechanisms have been proposed to explain why reovirus replication occurs unchecked selectively in malignant cells, less is known regarding the exact mechanism of reovirus-induced cell death . Our initial gene expression profiling experiment demonstrated that Reolysin treatment induced a strong IFN-b response. This is not surprising given that previous studies have demonstrated that this antiviral response may limit reovirus replication in nontransformed cells (Rudd and Lemay, 2005; Shmulevitz et al., 2010) . However, it is also possible that IFN stimulation may contribute to Reolysin's anti-tumor activity (Taylor et al., 2008) . Therefore, IFN production may both contribute and interfere with Reolysin's anticancer activity. Neutralization of IFN-b did not alter Reolysin-mediated apoptosis in U266 and RPMI-8226 MM cells in vitro, suggesting that other mechanisms are likely involved. Interestingly, our gene expression data also revealed upregulation of many ER stress-related genes, including a strong induction in NOXA. The high protein synthesis rates of MM cells (compared with low protein synthesis rates of normal cells) may render them uniquely sensitive to ER stress-mediated apoptosis (Meister et al., 2007; Nawrocki et al., 2008) . Earlier studies have demonstrated that bortezomib-induced NOXA expression and ER stress-mediated apoptosis in MM cells is a result of a large accrual of ubiquitinated proteins (Fernandez et al., 2005; Qin et al., 2005; Perez-Galan et al., 2006; Gomez-Bougie et al., 2007; Nawrocki et al., 2008; Wang et al., 2009) . Similarly to proteasomal inhibition, unchecked viral replication in malignant cells leads to an accumulation of viral proteins. Several reports have highlighted the importance of ER stress in the response to viral infection (Jordan et al., 2002; Su et al., 2002) . The ER is essential for the folding and posttranslational modification of viral proteins. However, when unfolded proteins accumulate beyond the capacity of the ER, the ER stress response is activated and stimulates apoptosis. Considering this, we hypothesized that Reolysin may kill MM cells through an ER stressmediated mechanism. Our data showed that Reolysin treatment induced many characteristics of ER stress, including ER swelling, increased expression of CASPASE-4, GADD153/CHOP, GADD34, BiP, NOXA and XBP-1s, and higher intracellular calcium levels. In addition, ER stress-related gene expression was significantly induced in Figure 7 Reolysin possesses activity alone and enhances the activity of bortezomib in the 5TGM1 bone disease syngeneic MM mouse model. (a) 5TGM1 cells are highly sensitive to the Reolysin/bortezomib combination in vitro. 5TGM1 cells were treated with 2 nM BZ and 300 PFU/cell Reolysin for 24 h and apoptosis was measured by PI staining and flow cytometry. The data are expressed as mean±s.d., n ¼ 3. *Indicates a significant difference compared with controls or **either single agent treatment, Po0.05. (b) At 24 h after the last treatment, serum samples were collected from three mice/group and IgG2bk levels were measured by ELISA. The data are expressed as mean±s.d. *Indicates a significant difference compared with controls or **single agent treatment, Po0.05. (c) Reolysin reduces MM bone disease and enhances the activity of bortezomib. In all, 1 Â 10 6 5TGM1-eGFP cells, cells were injected IV into C57BL/KaLwRijHsd mice. Bone disease was allowed to establish for 14 days and then mice were treated with 0.5 or 1 mg/kg bortezomib every 72 h, 5 Â 10 8 TCID 50 Reolysin once a week or both agents for 3 weeks. At 24 h after the last treatment, mice were imaged using the Xenogen animal imaging system. Each group contained eight animals and a representative image from each group is shown. Note fluorescence in vertebrae column and skull. Paws and tail fluoresce due to the presence of white fur, not disease. (d) Vertebrae column eGFP fluorescence (mean efficiency) was quantified using Living Image software from three mice/group. Representative images are shown. The data are expressed as mean±s.d. *Indicates a significant difference compared with controls or **single agent treatment, Po0.05.
primary MM cells and not in normal PBMCs. To the best of our knowledge, our data are the first to report induction of ER stress by Reolysin treatment as an anti-cancer mechanism of action of this viral therapy.
The induction of the BH3-only protein NOXA has recently been shown to have a significant role in the cascade of events that control ER stress-mediated apoptosis (Li et al., 2006; Nawrocki et al., 2008) . Accordingly, our investigation revealed that NOXA is an important regulator of Reolysin-induced apoptosis as shRNA-mediated knockdown of NOXA in MM cells significantly blunted its anti-myeloma activity. We and other investigators have demonstrated that ER stress and NOXA induction are essential events underlying bortezomib's anti-myeloma activity (Fernandez et al., 2005; Qin et al., 2005; Perez-Galan et al., 2006; Nawrocki et al., 2008) . Furthermore, the high immunoglobulin production of MM cells makes them vulnerable to ER stress-induced apoptosis. As such, we hypothesized that agents with the ability to stimulate ER stress and NOXA expression may augment the therapeutic effects of bortezomib. Our data support this hypothesis and establish that Reolysin and bortezomib work in concert to produce an accrual of viral and ubiquitinated proteins leading to enhanced levels of ER stress and NOXA induction. These events are critical for the anti-cancer efficacy of the Reolysin/bortezomib combination as the translation inhibitor cycloheximide severely impaired its ability to induce apoptosis.
Reovirus infection remains an attractive cancer therapeutic strategy as its selective ability to replicate in tumor cells results in low toxicity. However, it may be most effective when utilized in combination with conventional chemotherapy (Harrington et al., 2010) . Recent studies have used cyclophosphamide, gemcitabine or cisplatin to improve the activity of Reolysin in solid tumors (Smakman et al., 2006; Qiao et al., 2008; Pandha et al., 2009; Sei et al., 2009) . The enhanced cytotoxicity observed of the addition of these compounds to reovirus therapy has been largely attributed to suppression of the anti-viral immune response. Bortezomib may also have immunosuppressive effects, which could account for some of the activity of this combination in vivo. Bortezomib has been shown to inhibit plasma cells, dendritic cells and the generation of graft-versus-host disease (Sun et al., 2004; Nencioni et al., 2006; Neubert et al., 2008) . However, the Reolysin/bortezomib combination displayed potent efficacy in both a human xenograft model in SCID mice and a syngeneic model in immunocompetent mice, suggesting that the therapeutic effects of this combination involves direct tumor cytotoxicity, rather than complete dependence upon an immune response. Accordingly, enhanced levels of NOXA induction and active caspase-3 levels were detected in combinationtreated tumors. Another recently used strategy to augment oncolytic virus therapy is to target the tumor microenvironment (Rhim and Tosato, 2007) . Inhibition of angiogenesis with bevacizumab, sunitinib, cyclic arginine-glycine-aspartic (cRGD) peptide or mammalian target of rapamycin (mTOR) inhibitors has been reported to enhance the anti-tumor effects of oncolytic viruses (Homicsko et al., 2005; Kurozumi et al., 2007; Libertini et al., 2008; Kottke et al., 2010) . Since bortezomib inhibits nuclear factor kB activity, reduces vascular endothelial growth factor (VEGF) levels and decreases angiogenesis (Sunwoo et al., 2001; Nawrocki et al., 2002; Roccaro et al., 2006) , modulation of vascular permeability may also account for some of the promising activity observed in vivo with the Reolysin/bortezomib combination. However, our data demonstrate that stimulation of ER stress and NOXA expression by Reolysin significantly contributes to its ability to enhance bortezomib's anti-myeloma activity. Importantly, the Reolysin/ bortezomib combination also displayed strong efficacy in a MM bone disease mouse model that closely mimics the pathogenesis of MM observed in humans (Figure 7) .
Bortezomib therapy has led to substantial improvements in clinical outcomes for patients with MM. However, relapse occurs in the vast majority of patients and new therapeutic approaches are needed for patients with refractory disease. We have shown that Reolysin has potent anti-cancer activity in MM cells. Furthermore, Reolysin significantly increases the efficacy of the frontline standard of care agent bortezomib through the concurrent accumulation of viral and ubiquitinated proteins culminating in the induction of NOXA-regulated ER stress-mediated apoptosis. The Reolysin/bortezomib combination represents a highly effective, well-tolerated novel therapeutic approach for the treatment of MM that warrants investigation in clinical trials.
Materials and methods
Cells and cell culture RPMI-8226, U266 and NCI-H929 MM cell lines and HeLa cells were obtained from American Type Cell Culture Collection (ATCC, Manassas, VA, USA). LP-1 and KMS-12-BM were purchased from the DSMZ (Braunschweig, Germany). MM cell lines were maintained in RPMI-1640 media supplemented with 10% fetal bovine serum in a humidified incubator 37 1C with 5% CO 2 . The characterization and culture of the 5TGM1 murine MM cell line has been previously reported (Oyajobi et al., 2007) . Normal PBMCs were purchased from Stem Cell Technologies, Vancouver, BC Canada. Primary cells from MM patients were collected following informed consent of an Institutional Review Board (IRB)-approved protocol. CD138-positive cells were selected using beads from Miltenyi Biotec (Auburn, CA, USA) and used in all experiments.
Antibodies and reagents
Antibodies were obtained from the following commercial sources: anti-NOXA (Calbiochem, Gibbstown, NJ, USA, for immunoblotting and Novus Biologicals, Littleton, CO, USA for immunohistochemistry (IHC), anti-tubulin (Sigma-Aldrich, St Louis, MO, USA) anti-active caspase-3 and BiP (Cell Signaling, Beverly, MA, USA) and anti-ubiquitin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Anti-reovirus antibody and Reolysin were kindly provided by Oncolytics Biotech Inc. (Calgary, AB, USA) Cycloheximide was purchased from Sigma-Aldrich. Bortezomib (Velcade) was obtained from the CTRC hospital pharmacy. Rabbit anti-IFN-b antisera was purchased from PBL Interferon Source (Piscataway, NJ, USA).
Quantification of drug-induced cytotoxicity
Cell viability was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The pro-apoptotic effects of Reolysin and bortezomib were quantified by PI (propidium iodide) staining and FACS (fluorescence activated cell sorting) analysis of sub-G 0 /G 1 DNA and quantification of active caspase-3-positive cells by flow cytometry using a commercial kit (BD Biosciences, San Jose, CA, USA) as previously described (Nawrocki et al., 2008) .
Transmission electron microscopy Cells were fixed as previously described to examine endoplasmic reticulum morphology and reovirus accumulation .
shRNA transfection MM cells were infected with lentivirus encoding an shRNA sequence specific for NOXA (sc-37305-V) or Control shRNA (sc-108080) (Santa Cruz Biotechnology). Infected cells were selected with constant culture in 1 mg/ml puromycin. NOXA knockdown was confirmed by immunoblotting.
Measurement of intracellular Ca
2 þ levels RPMI-8266 and U266 cells were treated with indicated concentrations of Reolysin and bortezomib or both for 12 h. Cells were collected, washed in phosphate-buffered saline (PBS) and incubated with 1 mmol/l calcium green-1 (Invitrogen, Carlsbad, CA, USA) for 30 min. Cells were then harvested and washed in PBS. Fluorescence was quantified using a FACSCanto II with CellQuest Pro Software (BD Biosciences).
Immunoblotting Cells were treated with the indicated concentrations of drugs, lysed and immunoblotting was preformed as previously described (Nawrocki et al., 2008) .
Confocal microscopy RPMI-8226 and U266 cells were centrifuged onto glass slides following treatment with Reolysin, bortezomib or both and fixed in methanol, permeabilized and stained with anti-ubiquitin or anti-reovirus antibodies as previously described . HeLa cells were cultured in chamber slides and treated under identical conditions to MM cell lines. Cells were mounted using Prolong Gold with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Invitrogen). Images were captured using a Zeiss LSM 510 Meta confocal microscope with an oil Â 40 objective using Zen software (Zeiss, Oberkochen, Germany).
Expression microarrays U266 cells were treated with 300 PFU/cell Reolysin for 48 h. Following drug treatment, total RNAs were isolated using the RNeasy Plus Mini Kit (Qiagen, Rockville, MD, USA) and treated with TURBO DNA-free Kit (Applied Biosystems, Foster City, CA, USA). In all, 300 ng of total RNA per sample was amplified and hybridized to GeneChip Human Gene 1.0 ST arrays (Affymetrix, Inc., Santa Clara, CA, USA) according to the manufacturer's instructions. Affymetrix CEL files were imported into Partek Genomics Suite 6.4 (Partek Inc., St Louis, MO, USA) using the default Partek normalization parameters and the RMA (robust multiarray average) analysis adjusted for probe sequence and GC content (GCRMA). Data normalization was performed across all arrays using quantile normalization.
Quantitative real-time polymerase chain reaction Cells were treated with 300 PFU/cell Reolysin and/or 2 nM bortezomib. cDNA from control-treated cells were used for relative quantification by RT-PCR analyses. First-strand cDNA synthesis was performed from 1 mg RNA in a 20-ml reaction mixture using the high-capacity cDNA Reverse Transcription Kit (Applied Biosystems). CASPASE-4, CHOP/GADD153, GADD34, HSPA5/BiP, BIM, PUMA and NOXA transcripts were amplified using commercially available TaqMan Gene expression assays (Applied Biosystems). XBP-1s qRT-PCR was designed to span the 26 basepair intron to anneal only the spliced mRNA. Primers and TaqMan probe sequences are as follows: forward primer: 5 0 -cctggttgctgaagaggag-3 0 reverse primer: 5 0 -agtcaataccgccagaatcc-3 0 probe: 5 0 (Fam)-cctgcacctgct gcggactc-3 0 (Tamra). GAPDH was used as a housekeeping gene.
MM xenograft model RPMI-8226 cells (1 Â 10 7 ) were implanted into SCID mice. Treatment was initiated when tumors reached B200 mm 3 in size. Mice were treated with 0.5 mg/kg bortezomib IV every 72 h, 1 Â 10 7 TCID 50 Reolysin IV once a week or both agents for 2 weeks. Tumor volume was measured twice a week.
Syngeneic MM mouse model
In all, 1 Â 10 6 5TGM1-eGFP murine MM cells were injected IV into C57BL/KaLwRijHsd mice (Harlan, Indianapolis, IN, USA). After 14 days, mice were treated with 0.5 or 1.0 mg/kg bortezomib IV every 72 h, 5 Â 10 8 TCID 50 Reolysin once a week or both agents for 3 weeks. At 24 h after the last treatment, representative animals were euthanized, serum was collected and mouse skeletons were imaged using the Xenogen animal imaging system. Levels of GFP were quantified using Living Image software (Caliper Life Sciences, Hopkinton, MA, USA).
Measurement of serum IgG2bk levels 5TGM1 MM cells secrete IgG2bk. Serum samples were collected 24 h after the last drug treatment and IgG2bk levels were determined by enzyme-linked immunosorbent assay as described previously (Dallas et al., 1999) .
Immunohistochemistry
Paraffin-embedded tumor sections were deparaffinized in xylene, a graded series of alcohol and rehydrated in PBS. Heat-induced epitope retrieval on paraffin-embedded sections was performed by microwaving slides in a citrate buffer for 5 min. Endogenous peroxides were blocked with a 3% hydrogen peroxide solution for 10 min. Slides were then incubated in a protein block solution (5% horse and 1% goat serum in PBS) for 20 min. BiP, cleaved caspase-3 and NOXA antibodies were diluted in the protein block solution and placed at 4 1C overnight. After washing with PBS, slides were incubated in goat anti-rabbit horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at ambient temperature. Positive reactions were visualized using 3,3 0 -diaminobenzidine diaminobenzidine (Dako, Carpinteria, CA, USA) for 10 min. The slides were rinsed with water followed by a brief counterstain with Gill's hematoxylin (Sigma). Images were captured using an Olympus fluorescent microscope (Center Valley, PA, USA), with a DP71 camera and a Â 20 objective. Image-Pro Plus software Version 6.2.1 (MediaCybernetics, Bethesda, MD, USA) was used for image acquisition. ImageJ software (National Institutes of Health, Bethesda, MD, USA) was used for quantification of NOXA and BiP levels by densitometric analysis of five random fields containing viable tumor cells. Quantification of cleaved caspase-3 was conducted by counting the number of positive cells in five random fields.
Statistical analyses
Statistical significance between samples was determined using the Tukey-Kramer comparison test or the Student's t-test as appropriate. Differences were considered significant in all experiments at Po0.05.
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